Share to
Anti-Payload-DXD Antibody
Email:
htm0086@vip.163.com
Still deciding? Let’s start with a sample.Contact us!
Category
- Description
-
Anti-Payload-DXD Antibody
Antibody–drug conjugates (ADCs) are a class of promising biologic therapeutics designed to selectively deliver highly cytotoxic payloads to tumor cells while sparing normal tissues. They can be regarded as prodrugs: they remain stable in the bloodstream, minimizing drug release during circulation, and are efficiently converted into active drugs at the tumor site. To engineer the optimal tripartite combination of monoclonal antibody (mAb), linker, and payload, it is essential to monitor and understand the pharmacokinetic and pharmacodynamic properties of these three components in both the systemic circulation and the tumor microenvironment. In particular, the linker plays a critical role in determining the potency and safety profile of ADCs; therefore, in vivo monitoring of its behavior is indispensable. Drug-Connector Stability “It is crucial for selecting the appropriate type of connector, which is achieved by determining the pharmacokinetics ( pharmacokinetics, PK ) is implemented through parameters.
The PK properties of the ADC are determined by assessing the following three entities:
(1) Conjugates (antibodies conjugated to at least one drug);
(2) Total antibody (antibody not conjugated with a drug);
(3) Free drug and its metabolites as physical entities. The focus is on the key analytical methods (ELISA, TFC-MS/MS, and HRMS) used to evaluate the PK parameters of these three entities, thereby enabling the assessment of drug–linker stability in ADCs.
Topoisomerase I inhibitors represent the most recently FDA-approved class of antibody–drug conjugate payloads. Topoisomerases are located in the cell nucleus and function to regulate and repair DNA supercoiling and entanglement that occur during DNA unwinding, transcriptional elongation, and DNA replication. DXD is an inhibitor of DNA topoisomerase I; topoisomerase inhibitors specifically bind to the interface of the DNA–topoisomerase complex, thereby inhibiting the topoisomerase-mediated repair mechanism, inducing DNA damage, and ultimately triggering apoptosis. The next-generation DXD–ADC conjugates employ DXD as the cytotoxic payload; due to its short plasma half-life, it helps minimize toxic side effects while exhibiting robust cell-membrane permeability and a bystander effect that enables it to kill neighboring tumor cells, further contributing to its shortened half-life.
DXD – Next-Generation ADC Payload
ADC-Pharmacokinetics (PK)
The pharmacokinetic profile of ADCs shares similarities with that of conventional antibody drugs, yet it is also influenced by the properties of the conjugated payload. The incorporation of a small-molecule drug into the ADC structure can increase its heterogeneity. When evaluating the pharmacokinetics of ADCs, researchers often analyze multiple analytes, including bound antibody, total antibody, bound effector molecule, free small-molecule cytotoxic agent, and their analogs.
The impact of ADC drugs on antibody concentrations in the body
The conjugation of drugs to antibodies can influence the antibody’s in vivo distribution, metabolism, and clearance rate, thereby affecting both the therapeutic efficacy and safety of the drug. Studies have shown that conjugation with small-molecule toxins increases the clearance rate of antibodies, and that the higher the drug–antibody ratio (DAR) in an ADC, the faster the ADC is cleared from the body. This indicates that drug conjugation accelerates antibody clearance, and a high DAR may further enhance this effect; such a mechanism represents one of the key features of ADCs in cancer therapy.
Clearance pathways for reduced ADC drug concentrations
1. Degradation of the antibody moiety via enzymatic hydrolysis and other mechanisms: The antibody component of ADC drugs may be degraded by enzymes in vivo through metabolic pathways, leading to a reduction in the overall concentration of the ADC.
2. Complete dissociation of the cytotoxic payload from the antibody (i.e., DAR = 0): This means the cytotoxic molecule has detached from the antibody and lost its ability to bind to it.
ADC Drug Degradation Pathways
Evaluation of the in vivo loss rate of ADC drugs
The drug loss rate refers to the extent of loss of the cytotoxic payload in antibody–drug conjugates (ADCs). In ADCs, the cytotoxic payload is typically delivered selectively by covalently linking it to the antibody. Drug loss can reduce target specificity and therapeutic efficacy, and may even lead to adverse reactions. Therefore, assessing the in vivo drug loss rate is a critical step in the research and development of preclinical ADCs, as well as in evaluating their safety and efficacy.
The substantial discrepancy between antibody PK and total antibody PK indicates significant variability in the rate of drug loss or degradation within the body. The difference in the rate of change of antibody concentration and the clearance rate of the ADC drug indirectly reflects the stability of the ADC in the bloodstream, as it influences the duration of drug residence in the body and its therapeutic efficacy.
The clearance rate of ADC drugs is often higher than that of the total antibody concentration. Both drug degradation and the intrinsic clearance of the ADC itself contribute to the decline in intracellular drug concentrations, whereas the total antibody concentration is influenced solely by the clearance rates of the ADC and the unbound antibody. If the total antibody declines more rapidly while the ADC drug clearance rate remains low, this may indicate a slower drug release from the ADC in vivo. Possible mechanisms include overly strong binding between the drug and the antibody or impediments in the drug-release mechanism. Total antibody and conjugated antibody levels are typically quantified using enzyme-linked immunosorbent assay (ELISA), whereas free and bound drug as well as metabolic degradation products are usually analyzed by liquid chromatography–mass spectrometry (LC-MS).
To support the pharmacokinetic analysis of DXD-ADC, Heyou Sheng Bio has launched the DXD Monoclonal Antibody, a product that Characterized by high specificity, high stability, and high sensitivity , antibodies capable of effectively determining the stability and release efficiency of DXD can be used for Plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug-binding affinity, DAR value analysis, and evaluation of the therapeutic efficacy of ADC drugs. To accelerate the development of DXD-ADC drugs and provide a basis for their preclinical application and dose optimization.
Advantages of DXD Antibody Products
★ High purity: Verified by SDS-PAGE, with a purity greater than 90%;
DXD antibody on SDS-PAGE under reducing (R) conditions. The protein purity is greater than 90%.
★ High affinity: can bind DXD with high affinity;
Binding Activity of ADC-1(DXD) with Anti-DXD Antibody: Assessed by its binding capacity in a functional ELISA. Immobilized ADC-1(DXD) at 1 μg/mL binds the anti-DXD antibody, with an EC50 of 2.298–10 ng/mL.
★ DXD monoclonal antibody PK application assay demonstration:
Sample EC50 (μg/mL) Plasma 0.0073 2%BSA 0.0044 For more details on HeYouSheng Bio’s DXD products, please contact our sales representative or scan the QR code below to request a sample.
Contact: Mr. Xie, 15201775322.
Related document downloads:
Consult Now
Please note: Kindly provide your contact information, and our dedicated professionals will get in touch with you as soon as possible!
